TABLE 3.
Treatments received by COVID-19 patients1
| Variable | Alive, n = 360 (76.3%) | Deceased, n = 112 (23.7%) | P value |
|---|---|---|---|
| Remdesivir | |||
| No | 305 (85.0%) | 91 (81.3%) | |
| Yes | 55 (15%) | 21 (18.7%) | 0.37 |
| Dexamethasone | |||
| No | 268 (74.7%) | 76 (67.9%) | |
| Yes | 92 (25.3%) | 36 (32.1%) | 0.18 |
| Vitamin D supplements | |||
| No | 256 (71.1%) | 80 (71.4%) | >0.999 |
| Yes | 100 (27.8%) | 31 (27.7%) | |
| Not recorded | 4 (1.1%) | 1 (0.8%) | |
| Oxygen | |||
| No | 144 (40.0%) | 2 (1.8%) | |
| Yes | 216 (60.0%) | 110 (98.2%) | <0.001 |
| ICU | |||
| No | 318 (88.3%) | 78 (68.8%) | |
| Yes | 42 (11.7%) | 34 (31.2%) | <0.001 |
| CPAP | |||
| No | 321 (89.2%) | 88 (78.6%) | |
| Yes | 39 (10.8%) | 24 (21.4%) | 0.48 |
| Mechanical ventilation | |||
| No | 334 (93.0%) | 82 (73.2%) | |
| Yes | 26 (7.0%) | 30 (26.8%) | <0.001 |
1
A univariate analysis was performed to compare variables across alive and deceased categories using a chi-squared test for categorical variables and a Mann-Whitney U test for continuous variables. Categorical data are represented as counts and percentages and continuous variables as medians and IQRs. COVID-19, coronavirus disease 2019; CPAP, continuous positive airways pressure; ICU, intensive care unit.